A34-30 Patients With Chronic Obstructive Pulmonary Disease With Exacerbations and Triple Therapy Linked to Increased Clinical and Economic Burden: US Database Claims Analysis

Rationale There are limited US real-world data on the clinical profile and healthcare resource utilization (HCRU) of patients with chronic obstructive pulmonary disease (COPD) with exacerbations and triple therapy use. Methods This real-world retrospective descriptive study used claims data from the Komodo Research Database (01/2016-12/2023). Eligible patients had continuous insurance eligibility and ≥2 COPD diagnoses in the year of interest (2019-2023) or earlier. The primary endpoint was COPD-related HCRU. Secondary endpoints included COPD-related healthcare costs. Annual US prevalence of COPD was estimated by counting the number of patients within age/sex strata, then standardizing to the US census age/sex distribution. Results In 2019, 1,413,727 patients with COPD were identified (including 79,712 patients receiving inhaled triple therapy with ≥2 moderate or ≥ 1 severe exacerbation [ITT-Ex]), which increased to 1,694,339 (including 103,673 ITT-Ex) in 2023. The annual US prevalence of COPD in 2019 was 2537/100,000 people, increasing to 3093/100,000 people in 2023. Demographics and clinical characteristics in the ITT-Ex and overall patient populations are presented in the Table. In the ITT-Ex group and overall population, the highest rate of moderate/severe exacerbations per patient-year (PPY) was in 2019 with a mean (standard deviation [SD]) of 2.95 (1.74) and 0.80 (1.36), respectively. COPD-related inpatient visits PPY were highest in 2019, decreasing through 2023 from 0.73 (1.21) to 0.65 (1.13) in the ITT-Ex group, and 0.15 (0.64) to 0.11 (0.56) in the overall population. COPD-related emergency department visits PPY were highest in 2019 in both the ITT-Ex and overall population: 0.65 (2.08) and 0.15 (1.05), respectively, decreasing to 0.59 (2.49) and 0.11 (1.01) in 2023, respectively. COPD-related outpatient visits PPY were highest in 2019 and decreased through 2023 in both groups, from 8.61 (18.74) to 7.22 (20.52) in the ITT-Ex group, and from 2.25 (10.52) to 1.83 (10.90) in the overall population. Total COPD-related healthcare (medical and pharmacy) costs per patient per year were greatest in 2019 and decreased through 2023, from $20,607 ($30,670) to $17,823 ($29,789) in the ITT-Ex group, and from $4,702 ($16,639) to $3,756 ($13,942) overall. The lower costs observed in the overall population likely reflect the inclusion of a larger pool of patients with COPD, including those with milder disease severity. Conclusions Patients with COPD and exacerbations treated with inhaled triple therapy experience a greater clinical and economic burden than the overall COPD population, highlighting an unmet need of targeted therapy in this patient subset. Funding GSK (300072). This abstract is funded by: GSK (300072)